The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 29, No. 10, pp. 1042-1044.
© 1995 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holle, L.
Right arrow Articles by Collins, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holle, L.
Right arrow Articles by Collins, D.

Research Articles

Valproate in status epilepticus

LM Holle, BE Gidal, and DM Collins

In patients with intractable status epilepticus who have not responded to therapy with benzodiazepines, phenytoin, and barbiturates, valproate may be a reasonable option. Extemporaneously prepared valproate rectal suppositories or retention enemas have been given in dosages of 200-1200 mg q6h in addition to phenytoin, phenobarbital, or both in adults. The pediatric dose used was 15-20 mg/kg, in addition to phenytoin and/or phenobarbital.


This article has been cited by other articles:


Home page
 NeurologyHome page
R. D. Sheth and B. E. Gidal
Intravenous valproic acid for myoclonic status epilepticus
Neurology, March 14, 2000; 54(5): 1201 - 1201.
[Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1995 by Harvey Whitney Books Company.